Canlyniadau Chwilio

Warfarin and vitamin K intake in the era of pharmacogenetics gan Yael Lurie, Ronen Loebstein, Daniel Kurnik, Shlomo Almog, Hillel Halkin

Cael y testun llawn Cael y testun llawn

<i>CYP4F2</i> rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement gan Hanjing Cen, Wu‐Tao Zeng, Xiuyu Leng, Min Huang, Xiao Chen, Jiali Li, Zhiying Huang, Huichang Bi, Xueding Wang, Yanling He, Fan He, Rui‐Na Zhou, Qi‐Shan Zheng, Lizi Zhao

Cael y testun llawn

Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects gan Mohi Iqbal Mohammed Abdul, Xiaorui Jiang, Kenneth M. Williams, Richard O. Day, Basil D. Roufogalis, Winston Liauw, Hongmei Xu, Andrew J. McLachlan

Cael y testun llawn

Facilitating pharmacogenetic studies using electronic health records and natural-language processing: a case study of warfarin gan Hua Xu, Min Jiang, Matt Oetjens, Erica Bowton, Andrea H. Ramirez, Janina M. Jeff, Melissa Basford, Jill M. Pulley, James D. Cowan, Xiaoming Wang, Marylyn D. Ritchie, Daniel R. Masys, Dan M. Roden, Dana C. Crawford, Joshua C. Denny

Cael y testun llawn Cael y testun llawn

Race influences warfarin dose changes associated with genetic factors gan Nita A. Limdi, Todd M. Brown, Qi Yan, Jonathan Thigpen, Aditi Shendre, Nianjun Liu, Charles E. Hill, Donna K. Arnett, T. Mark Beasley

Cael y testun llawn Cael y testun llawn

Pharmacogenomics of warfarin in populations of <scp>A</scp>frican descent gan Guilherme Suarez‐Kurtz, Mariana Rodrigues Botton

Cael y testun llawn

VKORC1 mutations detected in patients resistant to vitamin K antagonists are not all associated with a resistant VKOR activity gan Ahmed Hodroge, Benjamin Matagrin, Caroline Moreau, Isabelle Fourel, Abdessalem Hammed, Etienne Benoît, Virginie Lattard

Cael y testun llawn Cael y testun llawn

Population diversity and the performance of warfarin dosing algorithms gan Guilherme Suarez‐Kurtz

Cael y testun llawn

Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment gan Matthias Watzka, Christof Geisen, Carville G. Bevans, Katja Sittinger, Gabriele Spohn, Simone Rost, E. Seifried, C. R. Müller, Johannes Oldenburg

Cael y testun llawn Cael y testun llawn

A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance gan Ronen Loebstein, Ilana Dvoskin, Hillel Halkin, Manuela Vecsler, Aharon Lubetsky, Gideon Rechavi, Ninette Amariglio, Yoram Cohen, Gie Ken‐Dror, Shlomo Almog, Eva Gak

Cael y testun llawn Cael y testun llawn

<i>CYP2C9*8</i> is Prevalent Among African–Americans: Implications for Pharmacogenetic Dosing gan Stuart A. Scott, Malgorzata Jaremko, Steven A. Lubitz, Ruth Kornreich, Jonathan L. Halperin, Robert J. Desnick

Cael y testun llawn

A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon gan Talitha I. Verhoef, Georgia Ragia, Anthonius de Boer, Rita Barallon, Genovefa Kolovou, Vana Kolovou, Stavros Konstantinides, Saskia le Cessie, Efstratios Maltezos, F.J.M. van der Meer, Ken Redekop, M.G.H. Remkes, Frits R. Rosendaal, Rianne MF van Schie, Anna Tavridou, Dimitrios Tziakas, Mia Wadelius, Vangelis G. Manolopoulos, Anke H. Maitland‐van der Zee

Cael y testun llawn Cael y testun llawn

CYP4F2 genetic variant alters required warfarin dose gan Michael D. Caldwell, Tarif Awad, Julie A. Johnson, Brian F. Gage, Mat Falkowski, Paul J. Gardina, Jason Hubbard, Yaron Turpaz, Taimour Langaee, Charles Eby, Cristi R. King, Amy Brower, John R. Schmelzer, Ingrid Glurich, Humberto Vidaillet, Steven H. Yale, Kai Qi Zhang, Richard L. Berg, James K. Burmester

Cael y testun llawn Cael y testun llawn

Warfarin Sensitivity Genotyping: A Review of the Literature and Summary of Patient Experience gan Thomas P. Moyer, Dennis J. O’Kane, Linnea M. Baudhuin, Carmen Wiley, Alexandre Fortini, Pamela K. Fisher, Denise M. Dupras, Rajeev Chaudhry, Prabin Thapa, Alan R. Zinsmeister, John A. Heit

Cael y testun llawn Cael y testun llawn

Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans gan Whitney Hernandez, Eric R. Gamazon, Keston Aquino-Michaels, Shitalben Patel, Terence J. O’Brien, Arthur F. Harralson, Rick A. Kittles, Andrew P. Barbour, Matthew Tuck, Samantha D. McIntosh, J. Douglas, Dan L. Nicolae, Larisa H. Cavallari, Minoli A. Perera

Cael y testun llawn

Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9 gan Hersh Sagrieya, Caroline Berube, Alice Wen, Ramesh Ramakrishnan, Alain Mir, Amy L. Hamilton, Russ B. Altman

Cael y testun llawn

Dietary vitamin K influences intra‐individual variability in anticoagulant response to warfarin gan Tayyaba Khan, Hilary Wynne, Peter Wood, A. Torrance, C. R. Hankey, Peter Avery, Patrick Kesteven, Farhad Kamali

Cael y testun llawn Cael y testun llawn

Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements gan Kendra Ross, Abbigail W Bigham, Melissa Edwards, Agnes Gozdzik, Guilherme Suarez‐Kurtz, Esteban J. Parra

Cael y testun llawn Cael y testun llawn

<i>VKORC1</i> Polymorphisms, Haplotypes and Haplotype Groups on Warfarin Dose Among African–Americans and European–Americans gan Nita A. Limdi, T. Mark Beasley, Michael R. Crowley, Joyce A. Goldstein, Mark J. Rieder, David A. Flockhart, Donna K. Arnett, Ronald T. Acton, Nianjun Liu

Cael y testun llawn

Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy gan N. S. FERDER, C.S. EBY, E. DEYCH, Jenine K. Harris, Paul M. Ridker, Paul E. Milligan, Samuel Z. Goldhaber, Christopher R. King, Tusar Giri, Howard L. McLeod, Robert J. Glynn, Brian F. Gage

Cael y testun llawn Cael y testun llawn